Compare OFIX & CTMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OFIX | CTMX |
|---|---|---|
| Founded | 1987 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 622.1M | 596.2M |
| IPO Year | N/A | 2015 |
| Metric | OFIX | CTMX |
|---|---|---|
| Price | $15.51 | $4.16 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 6 |
| Target Price | ★ $21.50 | $6.50 |
| AVG Volume (30 Days) | 218.5K | ★ 2.1M |
| Earning Date | 11-04-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 50.22 |
| EPS | N/A | ★ 0.24 |
| Revenue | ★ $818,058,000.00 | $113,631,000.00 |
| Revenue This Year | $3.97 | N/A |
| Revenue Next Year | $5.84 | N/A |
| P/E Ratio | ★ N/A | $17.49 |
| Revenue Growth | ★ 4.31 | N/A |
| 52 Week Low | $10.24 | $0.40 |
| 52 Week High | $20.48 | $4.62 |
| Indicator | OFIX | CTMX |
|---|---|---|
| Relative Strength Index (RSI) | 50.21 | 57.36 |
| Support Level | $15.51 | $3.78 |
| Resistance Level | $16.04 | $4.20 |
| Average True Range (ATR) | 0.49 | 0.24 |
| MACD | -0.02 | -0.02 |
| Stochastic Oscillator | 44.41 | 73.88 |
Orthofix Medical Inc. is a medical device company delivering orthopedic and spine solutions to healthcare providers. The company has two main segments: global spine, including bone growth and healing therapies, spinal implants, and regenerative tissue products; and global orthopedics, providing products used in fracture repair, deformity correction, and bone reconstruction procedures. The majority of the company's sales come from the global spine segment in the United States. Orthofix distributes its products throughout North America, Europe, and several countries across the globe. The company provides solutions to hospitals, physicians, other healthcare providers, and patients.
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.